Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 2Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Bites and Stings 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT03340766 2024-10-17

HARBOUR

Amgen

Phase 1 Completed
31 enrolled 29 charts
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00274742 2015-01-16

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Amgen Research (Munich) GmbH

Phase 1 Completed
76 enrolled 15 charts
Lymphoid

Bites and Stings, Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡